Chengdu Kanghong wins CFDA nod as China’s first novel MAb
HONG KONG – The China Food and Drug Administration (CFDA) has approved the first novel monoclonal antibody (MAb) in China with global intellectual property rights. Compaq Sipp ophthalmic injection (conbercept), a VEGF receptor antagonist, for wet age-related macular degeneration (AMD), joins similar biologics – such as Avastin (bevacizumab) and Lucentis (ranibizumab) with blockbuster sales potential.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter